Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- MHLW Compiles New Clinical Assessment Guidelines on Neuropathic Pain Drugs
January 7, 2021
- MHLW Informs of New Guideline on Exemption from Bioequivalence Studies for Oral Drugs
January 7, 2021
- Govt Eager to Roll Out 1st COVID-19 Vaccine by Late February; PM Says Pfizer’s Japan Data Ready by Month-End
January 5, 2021
- AMED to Fund 14 Projects under CiCLE Program
January 5, 2021
- 3 API Manufacturing Repatriation Projects by Meiji, Nipro, Shionogi Adopted for MHLW Funding
January 5, 2021
- MHLW Approves Label Expansions for Olumiant, Gardasil, Lynparza and More
December 28, 2020
- MHLW Grants Orphan Status to 5 APIs
December 28, 2020
- Japan’s Drug Production Swells 37.3% to 9.5 Trillion Yen in 2019: MHLW Survey
December 28, 2020
- MHLW Drafts Guidelines for Use of Patient Registry Data in Regulatory Filing
December 25, 2020
- Japan Prepping to Expand Veklury Label beyond Severe COVID-19: PMDA
December 25, 2020
- Coronavirus Panel Draws Up Plan for Vaccination System, Priority
December 25, 2020
- Results of On-Site Probe into Kobayashi Kako Due Out Early Next Year, MHLW Eyes Biz Suspension
December 24, 2020
- MHLW to Disclose Members’ Names, Minutes of Drug Pricing, Cost-Effectiveness Analysis Organizations to Enhance Transparency
December 24, 2020
- Govt’s Reform Panel to Draw Up Framework by Next Summer for Permanent Telemedicine Rollout, with Reimbursement Policies
December 24, 2020
- MHLW’s FY2021 Budget Record 33 Trillion-Plus Yen
December 23, 2020
- MHLW Orders Label Revision for Xylocaine; Advising Careful Administration in Ears and Digits
December 23, 2020
- MHLW’s Health Policy Bureau Allocated 129 Million Yen for Setting Up R&D Promotion Network
December 23, 2020
- 700 Million Yen Allocated for COVID-19 Control Measures in FY2021: MHLW’s Pharm Safety Bureau
December 23, 2020
- 0.8% Add-On to Adjustment Rate Set to Soften Impact on Drug Distribution: MHLW
December 22, 2020
- MHLW Official Says Biz Suspension on Kobayashi Kako Inevitable
December 22, 2020
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…